Management of hyperlipidemia: New LDL-C targets for persons at high-risk for cardiovascular events

Medical Science Monitor

Volumn 12, Issue 2, 2006, Pages

  Balbisi, Ebrahim A ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Cholesterol; Complications; Coronary heart disease; Guidelines; Statins

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE; MYOPATHY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; WEIGHT REDUCTION;

ANTILIPEMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHOLESTYRAMINE; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE STYLE; NIACIN; RISK FACTORS;

EID: 32044435830     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Texas. American Heart Association, 2005
2. Castelli WP, Garrison RJ, Wilson PW et al: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986; 256(20): 2835-38
3. Stamler J, Daviglus ML, Garside DB et al: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to longterm coronary, cardiovascular, and all-cause mortality and to longevity. JAMA, 2000; 284(3): 311-18
4. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 1986; 256(20): 2823-28
5. Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA, 1987; 257(16): 2176-80
6. Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med, 1995; 332(8): 512-21
7. Foley KA, Simpson RJ Jr, Crouse JR III et al: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol, 2003; 92(1): 79-81
8. Ford ES, Mokdad AH, Giles WH, Mensah GA: Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation, 2003; 107(17): 2185-89
9. Grundy SM, Cleeman JI, Merz CN et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004; 110(2): 227-39
10. The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22
11. Shepherd J, Blauw GJ, Murphy MB et al: On behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-30
12. Sever PS, Dahlof B, Poulter NR et al: ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-58
13. Cannon CP, Braunwald E, McCabe CH et al: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350(15): 1495-504
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002; 288: 2998-3007
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA, 2001; 285: 2486-97
16. th ed. New York, NY: McGraw-Hill, 2001; 971-1002
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339(19): 1349-57
18. Sacks FM, Pfeffer MA, Moye LA et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335(14): 1001-9
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344(8934): 1383-89
20. Shepherd J, Cobbe SM, Ford I et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333(20): 1301-7
21. Downs JR, Clearfield M, Weis S et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998; 279(20): 1615-22
22. Knatterud GL, Rosenberg Y, Campeau L et al: Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation, 2000; 102(2): 157-65
23. Knopp RH: Drug treatment of lipid disorders. N Engl J Med, 1999; 341: 498-511
24. Olsson AG, Pears J, McKellar J et al: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol, 2001; 88(5): 504-8
25. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH: The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation, 2005; 111(23): 3051-57
26. Ridker PM: JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of lowdensity lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation, 2003; 108(19): 2292-97
27. Pan WJ, Gustavson LE, Achari R et al: Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol, 2000; 40(3): 316-23
28. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al: American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 2002; 106(8): 1024-28
29. Zetia (ezetimibe) package insert. Whitehouse Station, New Jersey: Merck & Co, Inc., 2004
30. Ballantyne CM, Blazing MA, King TR et al: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol, 2004; 93(12): 1487-94
31. Feldman T, Koren M, Insull W Jr et al: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol, 2004; 93(12): 1481-86
32. Goldberg AC, Sapre A, Liu J et al: Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc, 2004; 79(5): 620-29
33. Alderman JD, Pasternak RC, Sacks FM et al: Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol, 1989; 64(12): 725-29
34. Bays HE, Dujovne CA, McGovern ME et al: Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol, 2003; 91(6): 667-72
35. Brown BG, Zhao X-Q, Chait A et al: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 2001; 345(22): 1583-92
36. Sprecher DL, Abrams J, Allen JW et al: Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med, 1994; 120(7): 537-43
37. Balbisi EA: Hyperlipidemia-lower targets, greater challenges. Med Sci Monit. 2004; 10(11): LE21
38. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med, 2000; 160(4): 459-67
39. Mitka M: Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA, 2003; 290(17): 2243-45
40. Wilde Mathews A, Landers P: An FDA shift could transform market for statins: agency will consider allowing over-the-counter sales of cholesterol medicine. Wall Street Journal, 2003; November 12: A1
41. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation, 1994; 89(3): 1333-445
42. Smith DG, McBurney CR: An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Pharmacoeconomics, 2003; 21(Suppl.1): 13-23
43. Red book. Montvale, NJ: Medical Economics, 2003
44. Balbisi EA: New perspective on the management of hyperlipidemia. Med Sci Monit, 2004; 10(7): LE11
45. Johannesson M, Jonsson B, Kjekshus J et al: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med, 1997; 336(5): 332-36
46. Caro J, Klittich W, McGuire A: The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ, 1997; 315(7122): 1577-82